Niagen Bioscience is no longer trying to be only a nicotinamide riboside supplement company. The second-quarter print is the first clean look at an investment year in which the cash-generating Tru Niagen franchise is being asked to fund a telehealth injectable platform, a preclinical rare-disease program, and a brand refresh, all while the ingredient wholesale book shrinks under nicotinamide mononucleotide competition. Management frames this as the step from a nutritional product line to a multi-asset anti-aging company. The equity is now priced as if that step fails.
The consumer engine still works where Niagen controls the customer. Direct website sales rose 23 percent, and e-commerce grew even after a brief Amazon listing disruption in June. Tru Niagen now accounts for most of the company. What is not working is the partner channel. Food-grade and pharmaceutical-grade ingredient sales both fell, a large commercial partner bought less, and selling expense jumped to about a third of net sales. Operating income therefore compressed even though gross margin stayed near 65 percent. Cash at mid-year was nearly $67 million after the February sale of the analytical-standards book. First-half buybacks totaled $5 million.
The debate is whether this year's spending buys a second act or just a thinner first act. Full-year e-commerce is guided to grow in the low-to-mid teens. Niagen Plus and new skincare partnerships are not expected to matter until next year. A $50 million at-the-market facility now sits beside an open repurchase program. The remaining authorization is about $15 million. The question the next several quarters resolve is whether the cash engine keeps funding the platform without an equity raise, or whether the new shelf becomes the story.